240results about "Fused cells" patented technology

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

The invention discloses a monoclonal antibody which is specifically combined with a microtubule associated protein tau (microtubule associated protein with 217 Thrphorylation, pTau217) of which the 217 site is phosphorylated by threonine, and a preparation method of the monoclonal antibody. The invention provides an amino acid sequence of a variable domain of the monoclonal antibody, and an amino acid sequence of a complementary determining region (CDR) contained in the amino acid sequence of the variable domain of the monoclonal antibody. The monoclonal antibody disclosed by the invention has the capability of specifically recognizing and remarkably combining pTau217, and can be used for developing and producing pTau217 clinical in vitro diagnosis (IVD) medical equipment products based on an immunological detection principle as a reagent raw material.

Provided herein are antibodies and antigen binding portions thereof that specifically bind the 4Ig isoform of B7 homolog 3 protein (B7-H3), various compositions of such antibodies or antigen binding portions thereof, and recombinant nucleic acids encoding the antibodies and antigen binding portions thereof. Also provided are methods of using the antibodies or antigen binding portions thereof in therapeutics and diagnostics for cancer or inflammation.

The present invention relates to bispecific antibodies against claudin 18.2 and CD3, pharmaceutical compositions comprising said bispecific antibodies, and related uses in the treatment of cancer.

The present invention provides a novel anti-Aβ antibody capable of detecting an Aβ related peptide, a method for measuring an Aβ related peptide in a biological sample by immunochemically using the above-mentioned novel anti-Aβ antibody, and a kit. A monoclonal antibody that recognizes an Aβ related peptide, and is produced by a hybridoma deposited under the accession number NITE BP-02998 at the NITE Patent Microorganisms Depositary of the National Institute of Technology and Evaluation. An antibody-immobilized carrier that includes a carrier and the monoclonal antibody defined in claim 1 bound to the carrier. A kit for measuring an Aβ related peptide, comprising the antibody-immobilized carrier.

Disclosed herein are reagents, reagent kits, and culture media for activating and expanding immune cells in vitro. In some embodiments, the reagents, reagent kits, and culture media comprise a Quillaja saponin. In other embodiments, the reagents, reagent kits, and culture media comprise a squalene-based emulsion. Also disclosed are methods for activating and expanding immune cells in vitro using the reagents, reagent kits, and culture media.

This invention discloses a hybridoma cell line that secretes anti-polystyrene monoclonal antibodies and its applications. The hybridoma cell line includes PS-8, classified as Hybridoma cell line PS-8. The accession number for PS-8 is CCTCC NO: C2024144, the accession date is May 10, 2024, and the depositary institution is the China Center for Type Culture Collection (CCTCC), located at Wuhan University, No. 299 Bayi Road, Wuchang District, Wuhan City, Hubei Province. The hybridoma cell line provided by this invention can stably secrete anti-polystyrene monoclonal antibodies with high titer, good specificity, and high sensitivity, making it suitable for detection in reagent kits and possessing potential application value.

Provided herein are cells, enzymes, and methods for improved cannabinoid production.

To provide an antibody that inhibits the 5'→3' exonuclease activity of a DNA polymerase, or a fragment of the antibody.SOLUTION: Disclosed is an antibody that binds specifically to a 5'→3' exonuclease activity domain of a DNA polymerase, or a fragment of the antibody.SELECTED DRAWING: None

A cell culture device according to the present disclosure comprises: a culture chamber for culturing suspension cells; a flow path having a culture medium supply port and a culture medium discharge port, and provided adjacent to part or all of the outer side of at least one surface of the culture chamber; an oxygen permeable membrane provided to at least part of the flow path and / or the culture chamber; and a cell seeding port provided to at least part of the culture chamber.

The present invention discloses a genetically modified rodent whose immunoglobulin light chain locus is modified so as to comprise a single rearranged human immunoglobulin light chain gene V / J gene upstream of a mouse Kappa light chain locus constant region, a mouse variable region sequence cannot bind to an endogenous constant region to form a complete mouse light chain antibody, the rodents are capable of normally reproducing and producing human light chain-containing antibodies. The invention also provides a method of making the genetically modified rodent and a use of the rodent.

Described are nucleic acids that can be used for guide nucleic acid expression such as nucleic acids that comprise a polII promoter; an expression gene that is operably associated with the polII promoter; and a guide nucleic acid that is in the 3' untranslated region (UTR) of the expression gene. The expression gene may have a length of about 200, 225, 250, 275, 300, 325, or 350 nucleotides to about 375, 400, 425, 450, 475, 500, 525, 550, 575, or 600 nucleotides.

The present application provides a method for identifying the immune state of a subject, and a use of a reagent for detecting an IL-1R2 level in a sample from a subject in the preparation of products for identifying the immune state of the subject. The present application further provides an antibody that binds to human IL-1R2 and a use thereof, and a hybridoma cell producing the antibody that binds to human IL-1R2 and a use thereof.

The present invention provides isolated polypeptides capable of specifically binding to a protein target selected from LGALS9, CRP, BTLA, SAA, EGF, or FGA, or to a peptide thereof, especially under urinary conditions, which may be used for predicting in a urine sample of a subject suspected of having an infection whether the infection is a bacterial infection or a viral infection. The present invention further provides methods of diagnostics and treatment using the isolated polypeptides, and suitable diagnostic kits.

The present invention relates to a monoclonal antibody or an antibody fragment thereof that binds to an extracellular region of FCRL1, a hybridoma that produces the antibody, a nucleic acid comprising a nucleotide sequence that encodes the antibody or the antibody fragment thereof, a cell transformed with a vector comprising the nucleic acid, a method for producing the antibody or the antibody fragment thereof using the hybridoma or the transformed cell, an antibody-drug conjugate comprising the antibody or the antibody fragment thereof, a therapeutic agent and a diagnostic agent, each of which comprises the antibody or the antibody fragment thereof, and a therapeutic method and a diagnostic method for a disease associated with FCRL1 using the antibody, the antibody fragment thereof, or the antibody-drug conjugate comprising the antibody or the antibody fragment thereof.

Provided herein are antibodies or antigen-binding portions thereof that bind to STEAP1 and uses thereof. The antibody provided by the invention can be combined with STEAP1 of human, cynomolgus monkeys or mice, and the antibody provided by the invention has good affinity and internalization effect, and has the potential of preparing anti-tumor ADC drugs.

The present disclosure pertains to immune cells comprising chimeric antigen receptors (CARs) and methods of using immune cells comprising CARs.

Provided are TrkA agonistic antibodies, compositions comprising such antibodies, and methods of using such antibodies for the prevention and / or treatment of a disease or disorder.

The present disclosure relates to engineered cells expressing heterologous MUC1, MUC1-C or MUC1-C cytoplasmic domain for generating induced pluripotent stem cells that are autologous to a subject.

To provide bispecific antigen-binding constructs that bind HER2 with reduced aggregation of the antigen-binding constructs, and uses.SOLUTION: Provided are antigen-binding constructs that target HER2 with specific sequences, nucleic acids encoding them, vectors comprising the nucleic acids, cells comprising the vectors, pharmaceutical compositions comprising them, and uses thereof, such as in treating a subject having a HER2 expressing tumor, killing HER2 expressing tumor cells, or inhibiting the growth of HER2 expressing tumor cells.SELECTED DRAWING: None

The present invention relates to a novel anti-TPBG antibody containing Fc silencing mutations such as leucine (L) to alanine (A) substitutions (LALA mutations) at positions 234 and 235, an antibody-drug conjugate (ADC) based thereon, and therapeutic methods and their use, particularly relating to cancer treatment.

Provided herein is a protein from Tumebacillus sp. NITE BP-02779 having a peptidoglycan-decomposing activity. Provided herein is a protein comprising the amino acid sequence of SEQ ID NO: 2 (1-164) or the amino acid sequence of SEQ ID NO: 4 (1-493), or a protein comprising an amino acid sequence in which 1 to 10 amino acid residues of these amino acid sequences are substituted, deleted, inserted, or added, or an amino acid sequence having 90% or more identity to these amino acid sequences, and having a peptidoglycan-decomposing activity.

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

Provided are a bispecific antibody containing an anti-CLDN18.2 antibody, and a pharmaceutical composition and the use thereof. The bispecific antibody comprises a fist protein functional region and a second protein functional region, wherein the first protein functional region is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, and the second protein functional region targets a target different from CLDN18.2 (for example, CD47). The bispecific antibody has a good biological activity and anti-tumor application prospects.

The application belongs to the technical field of biological pharmacy, and particularly relates to a bovine-derived mouse anti-Brucella antibody and a preparation method and application thereof. A bovine-derived mouse anti-Brucella antibody is prepared by synthesizing a tandem epitope protein of Brucella OMP25 proteins of bovine species, sheep testis species and canine species, immunizing mice, preparing a monoclonal antibody, cloning CDR fragments in Hv and Lv regions of the antibody to corresponding positions of bovine-derived IgG, and then performing overall mutation modification on the recombinant IgG to perform bovine-derived modification. The bovine-derived mouse anti-Brucella antibody preparation has good immunogenicity and protection effect, and can block and inhibit the propagation and spread of Brucella of bovine species, canine species and sheep testis species in an animal body.

Provided herein are antibodies, antigen-binding portions thereof, and antibody peptide conjugates that specifically bind to neuropilin-1 (NRP1) and various compositions of such antibodies, antigen-binding portions, and antibody-peptide conjugates. The disclosure also provides nucleic acids encoding the antibodies, antigen-binding portions thereof, or antibody peptide conjugates; cells comprising the nucleic acids; and methods for producing the antibodies, antigen-binding portions thereof, or antibody peptide conjugates. Also provided are methods for using the antibodies or antigen-binding portions thereof in therapeutics and diagnostics for cancer.

The present disclosure generally relates to methods and in vitro systems for generation of mitochondria-depleted pluripotent stem cells, composite pluripotent stem cells, or non-human, tetraploid, mitochondria-depleted embryos. The disclosure further provides methods for use of cells or non-human embryos in regenerative medicine and drug screening.

Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naive pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naive PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naive PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

This disclosure provides, among other things, a transgenic chicken. In some embodiments, the transgenic chicken comprises B cells in which the endogenous immunoglobulin heavy chain locus comprises: (a) a functional immunoglobulin heavy chain gene comprising a nucleic acid encoding a heavy chain variable domain in which the CDR3 is in the range of 30-60 amino acids in length and comprises at least 2 cysteine residues; and (b) a plurality of pseudogenes that are operably linked to said functional immunoglobulin heavy chain gene and that donate, by gene conversion, nucleotide sequence to the nucleic acid encoding the heavy chain variable domain of (a), wherein the pseudogenes are upstream or downstream of the functional immunoglobulin heavy chain gene.

The present invention aims to provide a radiolabeled anti-CDH3 antibody having an excellent antitumor effect and a cancer therapeutic agent containing the same. The present invention relates to a 225 Ac-labeled anti-CDH3 antibody and a cancer therapeutic agent containing the same.